Logo

Atara Biotherapeutics Expands its Collaboration Agreement with Laboratoires Pierre Fabre to Develop and Commercialize Ebvallo Globally

Share this

Atara Biotherapeutics Expands its Collaboration Agreement with Laboratoires Pierre Fabre to Develop and Commercialize Ebvallo Globally

Shots:

  • Atara has granted Pierre Fabre the license to develop & commercialize Atara’s Ebvallo across the US & other global territories. Earlier, Pierre Fabre only had the rights to geographies incl. Europe, Middle East, Africa & other selected emerging markets
  • As per the extended agreement, Atara will receive an aggregate of $640M incl. $30M up front & is eligible to receive up to $610M in regulatory ($100M) & commercial ($510M) milestones, plus double-digit tiered royalties. Pierre Fabre will reimburse Atara for the expected global development costs of Ebvallo through BLA submission
  • Ebvallo is an allogeneic EBV-specific T-cell immunotherapy for EBV+ PTCL that has been approved in the EU & is marketed in Germany & Austria

Ref: PR Newswire | Image: Atara Biotherapeutics

Related Posts:-  Atara Biotherapeutics Ebvallo (tabelecleucel) Receives EC’s Approval for Epstein‑Barr Virus Positive Post‑Transplant Lymphoproliferative Disease

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions